Home / Reports

Reports

Pivotal clinical trials for infliximab biosimilars

Biosimilars of Johnson & Johnson’s blockbuster arthritis drug Remicade (infliximab), a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α), are currently under development.

Pivotal clinical trials for etanercept biosimilars

Biosimilars of Amgen/Pfizer’s blockbuster arthritis drug Enbrel (etanercept), a fusion protein produced by recombinant DNA, are currently under development.

Biosimilar events from 2013 to 2015

During the period of 2013 to 2015, biosimilars has been increasingly on the agenda around the world.  Biosimilars are making steady progress, as can be seen by the increasing number of events, including approvals for biosimilars around the world [1].

Payers in US getting ready for biosimilars

Payers in the US are getting ready for the advent of biosimilars, according to a report published by biotech giant Amgen.

Payers in US view biosimilars as a lower-cost branded option

Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report published by biotech giant Amgen.

Impact of antidepressant generics in Europe

Use of generic antidepressants may improve adherence and reduce the cost of pharmacotherapy for depression in European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Impact of breast cancer generics in Europe

Breast cancer generics can increase patient adherence and reduce healthcare budgets for European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Impact of hypertension generics in Europe

A report by the Germany-based Institute for Healthcare and Social Research (IGES) released in November 2015 found that generics of drugs to treat high blood pressure can increase patient adherence and reduce healthcare budgets for European countries.

Impact of generics on European budgets

A report by the Germany-based Institute for Healthcare and Social Research (IGES) released on 16 November 2015 found that generics could contribute to reducing healthcare budgets for European countries.

Generics market share in Europe

Generics make a major contribution to the European drug supply, according to a report by the by Germany-based Institute for Healthcare and Social Research (IGES).

Generics News Research General

more

Biosimilars News Research General

more